Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoine Kimmoun

Showing results (1-10 of 176) with videos related to

Pageof 18
Sort By:
Critical Care (London, England)|February 16, 2019
Predicting clinical outcome in patients undergoing VA-ECMOAntoine Kimmoun, Bruno Levy
Shock (Augusta, Ga.)|November 18, 2011
Treatment of myocardial dysfunction in sepsis: the Toll-like receptor antagonist approachAntoine Kimmoun, Bruno Levy
Intensive Care Medicine|November 12, 2025
When statistics reach their limits: lessons learned from the analysis of the 4D studyAntoine Kimmoun, Martin Dres
Critical Care (London, England)|February 4, 2015
Angiotensin II: a new approach for refractory shock management?Antoine Kimmoun, Bruno Levy
Critical Care (London, England)|January 11, 2014
AT1 receptor-associated protein and septic shock-induced vascular hyporeactivity: another 'magic bullet' in the pipe?Antoine Kimmoun, Bruno Levy
Current Opinion in Critical Care|June 6, 2019
Inotropes and vasopressors use in cardiogenic shock: when, which and how much?Bruno Levy, Julie Buzon, Antoine Kimmoun
Intensive Care Medicine|April 16, 2013
Improving blood oxygenation during venovenous ECMO for ARDSAntoine Kimmoun, Fabrice Vanhuyse, Bruno Levy
The New England Journal of Medicine|July 12, 2014
High versus low blood-pressure target in septic shockAntoine Kimmoun, Nicolas Ducrocq, Bruno Levy
Current Opinion in Critical Care|June 4, 2020
Vasopressor use in cardiogenic shockBruno Levy, Thomas Klein, Antoine Kimmoun
Current Vascular Pharmacology|March 20, 2013
Mechanisms of vascular hyporesponsiveness in septic shockAntoine Kimmoun, Nicolas Ducrocq, Bruno Levy
Pageof 18

Showing results (1-10 of 176) with videos related to

Sort By:
Pageof 18
Critical Care (London, England)|February 16, 2019
Predicting clinical outcome in patients undergoing VA-ECMOAntoine Kimmoun, Bruno Levy
Shock (Augusta, Ga.)|November 18, 2011
Treatment of myocardial dysfunction in sepsis: the Toll-like receptor antagonist approachAntoine Kimmoun, Bruno Levy
Intensive Care Medicine|November 12, 2025
When statistics reach their limits: lessons learned from the analysis of the 4D studyAntoine Kimmoun, Martin Dres
Critical Care (London, England)|February 4, 2015
Angiotensin II: a new approach for refractory shock management?Antoine Kimmoun, Bruno Levy
Critical Care (London, England)|January 11, 2014
AT1 receptor-associated protein and septic shock-induced vascular hyporeactivity: another 'magic bullet' in the pipe?Antoine Kimmoun, Bruno Levy
Current Opinion in Critical Care|June 6, 2019
Inotropes and vasopressors use in cardiogenic shock: when, which and how much?Bruno Levy, Julie Buzon, Antoine Kimmoun
Intensive Care Medicine|April 16, 2013
Improving blood oxygenation during venovenous ECMO for ARDSAntoine Kimmoun, Fabrice Vanhuyse, Bruno Levy
The New England Journal of Medicine|July 12, 2014
High versus low blood-pressure target in septic shockAntoine Kimmoun, Nicolas Ducrocq, Bruno Levy
Current Opinion in Critical Care|June 4, 2020
Vasopressor use in cardiogenic shockBruno Levy, Thomas Klein, Antoine Kimmoun
Current Vascular Pharmacology|March 20, 2013
Mechanisms of vascular hyporesponsiveness in septic shockAntoine Kimmoun, Nicolas Ducrocq, Bruno Levy
Pageof 18